A Phase II Study on Allogeneic Stem Cell Transplantation in Patients With Active Acute Leukemia

Acute Leukemia Clinical Trial

— Gandalf-01  

Official title:

A Phase II Multicentre Open-label Study on Allogeneic Stem Cell Transplantation From Unrelated, Cord-blood and Family Haploidentical Donors in Patients With Active Acute Leukemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01814488
• Other study ID #: 2012-004008-37 Gandalf-01
• Status: Completed
• Phase: Phase 2
• Start date: July 2013
• Est. completion date: June 30, 2017

Study information

• Verified date: March 2023
• Source: Gruppo Italiano Trapianto di Midollo Osseo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The experimental treatment consists in the application of a therapeutic strategy of allogeneic transplantation as a potential curative procedure in a population of patients with chemoresistant acute leukemias.

Therapeutic intervention, namely the conditioning regimen as well as GVHD prophylaxis, are based on regimens currently in standard use in the context of allogeneic transplantation.

Description:

The experimental treatment consists in the application of a therapeutic strategy of allogeneic transplantation using either a Marrow Unrelated Donor (MUD) or a Cord Blood (CB) unit or a family Haploidentical (Haplo) donor as a potential curative procedure in a population of patients with chemoresistant acute leukemias for increase the overall survival in this patients.

Therapeutic intervention, namely the conditioning regimen as well as GVHD prophylaxis, are based on regimens currently in standard use in the context of allogeneic transplantation.

The Data Safety Monitoring Board (DSMB) in collaboration with the Steering Committee (SC) will make periodic monitoring to ensure the safety of patients enrolled in to the study. In particular, DSMB will check the periodic safety reports of serious adverse events, the primary or secondary graft failure and treated related mortality (TRM) data generated by the Data Management Center. A safety report will be generated every 30 enrolled patients completed 100 days of follow-up.

The population for analysis in the trial will be the Intention to Treat (ITT) population. All patients enrolled in the study will be included in the ITT analysis.

This study will explore the feasibility, safety and efficacy of allogeneic stem cell transplantation from unrelated, cord-blood and haploidentical donor in patients with an active leukemia. Due to the lack of detailed information from literature and the absence of alternative curative options in this patient population, criteria for sample size assessment do not refer to a formal statistical power calculation. Therefore, GITMO will promote enrollment of all patients with active leukemia eligible to allogeneic SCT in all Italian centres with the aim to collect outcome variables in ITT in the widest and most representative cohort of this specific patient population.

The choice of 80 patients transplanted is based on feasibility reasons and the expected patient population with these characteristics referred to the main Italian Transplant Centres in two year. GITMO survey data on transplant activity points to an estimated accrual of 40 patients per year over a 24 months enrolment period. Criteria for defining sample size do not follow statistical power estimates in order to demonstrate difference between the alternative donor options.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 101
• Est. completion date: June 30, 2017
• Est. primary completion date: June 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

Diagnosis of Primary induction Failure or chemoresistant relapse in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) patients

Activation of an alternative donor search by the Italian Bone Marrow Donor Registry (IBMDR)

Age >=18<=70

Unavailability of a HLA-matched related donor (MRD)

Performance status: ECOG<=3

Written and signed informed consent

Life expectancy not severely limited by concomitant illness.

Exclusion Criteria:

Previous allogeneic transplant (autologous transplant is accepted)

Positive pregnancy test

Any active, uncontrolled infection.

-

Related Conditions & MeSH terms

• Acute Disease
• Acute Leukemia
• Leukemia

Intervention

Procedure:
• allogeneic transplant
Allogenic transplant using either a Marrow Unrelated Donor or a Cord Blood unit or a family Haploidentical donor. The conditioning regimen in standard use is: Thiotepa (Tepadina) i.v. 5 mg/kg/daily (total dose 10 mg/kg) day -7 and -6; Busulfan (Busilvex) i.v. 3,2 mg/kg/day (total dose 9,6 mg/kg) as a single daily dose day -5, -4, -3; Fludarabine i.v. 50 mg/m2 (total dose150 mg/m2) day -5, -4, -3. Primary antifungal prophylaxis is Micafungin 50 mg/die i.v. (1 mg/kg if <40 kg) day 0 to engraftment. After engraftment continue antifungal prophylaxis according to local practice.

Locations

Country	Name	City	State
Italy	Azienda Ospedaliera SS Antonio e Biagio	Alessandria
Italy	Policlinico	Bari
Italy	Divisione di Ematologia - Ospedali Papa Giovanni XXIII	Bergamo
Italy	Ospedale San Orsola	Bologna
Italy	Ospedale Regionale Generale- Divisione Ematologia	Bolzano
Italy	Ospedale Binaghi	Cagliari
Italy	Ospedale Oncologico Businco	Cagliari
Italy	Ospedale Ferrarotto - Ematologia	Catania
Italy	S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle	Cuneo
Italy	Cattedra di Ematologia - Azienda Ospedaliera di Careggi	Firenze
Italy	Ospedale Policlinico San Martino - IST	Genova
Italy	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico	Milano
Italy	Ospedale Niguarda Ca' Grande	Milano
Italy	Ospedale San Raffaele	Milano
Italy	Divisione Ematologia - Azienda Ospedaliera Universitaria - Policlinico -	Modena
Italy	Cattedra di Medicina Interna ed Ematologia - Ospedale S. Gerardo de' i Tintori - Università degli Studi di Milano	Monza
Italy	AO Ospedali Riuniti Villa Sofia - Cervello	Palermo
Italy	Dipartimento Oncologico La Maddalena	Palermo
Italy	Fondazione IRCCS San Matteo	Pavia
Italy	Dip. di Ematologia - Unità di Terapia Intensiva Ematologica per il Trapianto Emopoietico - Ospedale Civile di Pescara	Pescara
Italy	Ospedale G. Da Saliceto di Piacenza	Piacenza
Italy	Cattedra di Ematologia - Policlinico	Roma
Italy	Policlinico A. Gemelli	Roma
Italy	Policlinico Universitario Tor Vergata	Roma
Italy	U.O. di Ematologia e Trapianti di Midollo Osseo - Azienda Osp. S. Camillo-Forlanini / Padiglione Morgagni	Roma
Italy	Ematologia e Centro Trapianti Midollo Osseo - Ospedale IRCCS Casa Sollievo della Sofferenza	San Giovanni Rotondo
Italy	Ospedale San Giuseppe Moscato	Taranto
Italy	Azienda ospedaliera Città della Salute e della Scienza	Torino
Italy	Centro Trapianti Metropolitano	Torino
Italy	A.O. Santa Maria della Misericordia	Udine

Sponsors (1)

Lead Sponsor	Collaborator
Gruppo Italiano Trapianto di Midollo Osseo

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival (OS)	The overall survival at 2 years (from time of enrolment) of all patients enrolled in to the study (either transplanted or not).; This is the simplest outcome, defined as the probability of survival irrespective of disease state at any point in time. Patients alive at their last follow-up are censored. It is analyzed by the Kaplan-Meier method, Log-Rank Test and parametric or semiparametric survival models.	2 years from time of enrolment
Primary	Disease-Free Survival (DFS)	DFS is defined as the probability of being alive free of disease at any point in time. Thus, death or disease relapse are treated as events (1). Patients alive and free of disease at their last follow-up are censored. The statistical methods for the analysis of DFS are the same as for OS (Kaplan-Meier curve, Log-Rank Test and survival models).	2 years from enrolment
Primary	Relapse Incidence (RI)	RI is defined as the probability of having had a relapse before time t. Death without experiencing a relapse is a competing event. The correct method of analysis is therefore the estimation of the Cumulative Incidence curve, comparable by the Gray Test and, for the multivariate analysis, the application of the proportional hazard model for the sub-distribution of competing risks, by Fine and Gray. In studying relapse, sometimes the interest is not only in the estimation of the cumulative incidence curve, but also in the estimation of the hazard ratios for comparing groups of patients. It is therefore common to apply also a survival (Cox or parametric) model considering relapse as an event and death without relapse as a censoring (the response time is given by the minimum between time to relapse and time to death without relapse; as usual, a patient who is alive and free of relapse is also censored).	2 years from enrolment
Primary	Non-Relapse Mortality (NRM)	It is defined as the probability of dying without previous occurrence of a relapse, which is a competing event. The same indications as for the analysis of RI apply.	2 years from enrolment
Primary	Progression-Free Survival (PFS)	It is defined as the probability of being alive with no indication of disease progression (relapse is considered as progression for patients in CR). It is analyzed by KaplanMeier curve, Log-Rank Test and parametric or non-parametric survival models.	2 years from enrolment
Secondary	Haematopoietic Recovery	The day of engraftment is defined as the first day of 3 consecutive days with a persistent blood cell count above a predefined level: WBC 1 x 109/l PMN 0.5 x 109/l Platelets 50 x109 /l or 20x 10 9 /l Death without recovery is a competing event, while no engraftment at the last followup is to be considered as a censored observation. Relapse or disease progression could be considered (depending on the disease being studied) as further competing events: this must be discussed with the responsible physician.	participants will be followed for the duration of hospital stay, an expected average of 30 days
Secondary	Acute Graft-versus-Host Disease (aGvHD)	The available information in the EBMT data regard the date of onset and the maximum grade of aGvHD. It is therefore possible to estimate the probability of aGvHD in a competing risks setting (death is a competing event; whether relapse/progression is a competing event must be discussed with the physician). By definition, patients alive (relapse/progression-free) at day 100 without having experienced aGvHD are censored. If the dates of onset are missing for the majority of patients, the analysis can focus only on the occurrence of aGvHD, which is analyzed by a logistic regression model. This method would however be incorrect if there is a (non negligible) percentage of censored observations or if competing events occurred before day 100.	from date of transplant to until the date of first event of aCGVD assessed up to 100 days post transplant
Secondary	Chronic Graft-versus-Host Disease (cGvHD)	When possible, if information on the date of 1°occurrence of cGvHD is available, it should be analyzed as a time-to-event outcome, being death (and possibly relapse/progression) the competing event; data are censored for patients alive (relapse/progression-free) without episodes of cGvHD at last follow-up. Since cGvHD is defined only for patients surviving at least 100 days, the survival model should consider a left truncation at 100 days; alternatively, the time of occurrence of cGvHD must be computed from 100 days. If information on the timing of cGvHD is not available, the outcome considered is the occurrence, and the statistical model to be used is the logistic regression. Only patients surviving at least 100 days are considered to be at risk of developing cGvHD, therefore the analysis must be restricted to these patients. This analysis is of course not satisfactory because it does not take into account the occurrence of death and censoring.	from day +100 post transplant to until the date of first event to cGVHD assessed up to 2 years post enrolment